Nutriband Inc.
NTRBHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeNutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. With a market capitalization of $70.0M, it sits in micro-cap territory. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain.
Market Cap
$70.0M
Beta
1.93
P/E (TTM)
—
P/E (Fwd)
-25.04
EPS (TTM)
$-0.53
EPS (Fwd)
$-0.23
ROE
-100.8%
ROA
-53.5%
Cash
$3.4M
Total Debt
$219,719
Free CF
-$1.4M
52W Change
-18.1%
Annual Financials
Cash vs Debt
Where NTRB stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, NTRB finished 40.52% above its 150-day moving average ($4.27) and 39.86% above its 200-day moving average ($4.29). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NTRB overbought or oversold?
At the October 20, 2026 close, NTRB's RSI(14) was 28.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $3.4M in cash and $220K in debt, NTRB maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$1.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -100.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been relatively flat, moving from $2.1M (2023) to $2.0M (2026).
Nutriband Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing NTRB's risk profile alongside its fundamentals and technical indicators provides a more complete picture.